External quality assessment for laboratories in pan-India ILI/SARI surveillance for simultaneous detection of influenza virus and SARS-CoV-2.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2023
Historique:
received: 08 08 2023
accepted: 23 10 2023
medline: 1 12 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: epublish

Résumé

The Indian Council of Medical Research has set up a nationwide network of 28 laboratories for simultaneous surveillance of influenza virus and SARS-CoV-2 in ILI/SARI patients, using an in-house developed and validated multiplex real-time RTPCR assay. The aim of this study was to ensure the quality of testing by these laboratories by implementing an external quality assessment program (EQAP). For this EQAP, a proficiency test (PT) panel comprising tissue-culture or egg-grown influenza virus and SARS-CoV-2 was developed. The PT panel was distributed to all the participant laboratories, which tested the panel and submitted the qualitative results online to the EQAP provider. The performance of the laboratories was evaluated on qualitative criteria but cycle threshold (Ct) values were also gathered for each sample. On a qualitative basis, all the laboratories achieved the criteria of 90% concordance with the results of the PT panel provider. Ct values of different samples across the laboratories were within ≤ ±3 cycles of the corresponding mean values of the respective sample. The results of this EQAP affirmed the quality and reliability of testing being done for simultaneous surveillance of influenza virus and SARS-CoV-2 in India.

Identifiants

pubmed: 38026348
doi: 10.3389/fpubh.2023.1274508
pmc: PMC10679675
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1274508

Informations de copyright

Copyright © 2023 Potdar, Vijay, Vipat, Jadhav, Gupta and Aggarwal.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Clin Chem Lab Med. 2022 Jul 19;60(10):1586-1597
pubmed: 35852107
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Vaccine. 2018 Jun 22;36(27):3960-3966
pubmed: 29801998
J Clin Virol. 2012 Jul;54(3):245-50
pubmed: 22538096
PLoS One. 2012;7(5):e36374
pubmed: 22623954
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
Clin Chem Lab Med. 2020 Dec 16;59(5):987-994
pubmed: 33554519
Viruses. 2018 Sep 13;10(9):
pubmed: 30216988
Front Public Health. 2023 Oct 20;11:1218292
pubmed: 37927860
Lancet Infect Dis. 2018 Nov;18(11):1191-1210
pubmed: 30243584
PLoS One. 2022 Feb 8;17(2):e0263736
pubmed: 35134089
Euro Surveill. 2022 Oct;27(42):
pubmed: 36268736
Nat Rev Microbiol. 2018 Jan;16(1):60
pubmed: 29109554
Clin Chem. 2011 Dec;57(12):1670-80
pubmed: 21965556
Emerg Infect Dis. 2020 Oct;26(10):2353-2360
pubmed: 32723432
Viruses. 2022 Mar 17;14(3):
pubmed: 35337033
J Clin Pathol. 2014 Aug;67(8):651-5
pubmed: 24621574
Clin Chem Lab Med. 2020 Dec 04;59(5):845-856
pubmed: 33554535
Pathology. 2022 Jun;54(4):472-478
pubmed: 35440366
J Virol Methods. 2022 Mar;301:114441
pubmed: 34954305
BMC Cancer. 2019 Oct 22;19(1):978
pubmed: 31640622
Science. 2020 Oct 2;370(6512):22
pubmed: 33004496

Auteurs

Varsha Potdar (V)

Indian Council of Medical Research-National Institute of Virology, Pune, India.

Neetu Vijay (N)

Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi, India.

Veena Vipat (V)

Indian Council of Medical Research-National Institute of Virology, Pune, India.

Sheetal Jadhav (S)

Indian Council of Medical Research-National Institute of Virology, Pune, India.

Nivedita Gupta (N)

Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi, India.

Neeraj Aggarwal (N)

Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH